Drug control authority approves product registration of Zolgensma, Qdenga

PUTRAJAYA The 393rd Drug Control Authority meeting on Friday (Feb 8) approved the registration of Zolgensma, a cell and gene therapy product, for the first time since the product's control came into force on Jan 1, 2021.

Health director-general Datuk Dr Muhammad Radzi Abu Hassan said the approval was granted after spinal muscular atrophy (SMA) was classified as a rare disease in Malaysia and Zolgensma, which is used to treat the disease, was designated an orphan medicine.